Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia.

Overview

authors

Stahl, Maximilian

DeVeaux, Michelle

Montesinos, Pau

Itzykson, Raphaël

Ritchie, Ellen K.
Sekeres, Mikkael A
Barnard, John
Podoltsev, Nikolai A
Brunner, Andrew
Komrokji, Rami S
Bhatt, Vijaya R
Al-Kali, Aref
Cluzeau, Thomas
Santini, Valeria
Roboz, Gail J
Fenaux, Pierre
Litzow, Mark
Fathi, Amir T
Perreault, Sarah
Kim, Tae Kon
Prebet, Thomas
Vey, Norbert
Verma, Vivek
Germing, Ulrich
Bergua, Juan
Serrano, Josefina
Gore, Steven D
Zeidan, Amer M

publication date

July 2, 2018

published in

Leukemia & lymphoma Journal

Research

keywords

Antineoplastic Combined Chemotherapy Protocols
Hematopoietic Stem Cell Transplantation
Leukemia, Myeloid, Acute
Neoplasm Recurrence, Local

Identity

Scopus Document Identifier

85049603735

Digital Object Identifier (DOI)

10.1080/10428194.2018.1468893

PubMed ID

29963936

Additional Document Info

volume

60

issue

1